Knee replacement market seen reaching $20.83B by 2035

Market Research Future projects the global knee replacement market will grow from $13.79 billion in 2026 to $20.83 billion by 2035, lifted by aging populations, obesity, robotic surgery adoption and the shift of routine procedures to outpatient centers. The forecast points to stronger demand in the U.S. and Asia-Pacific, with robotics and ambulatory surgery reshaping how knee replacements are performed and paid for.

Why it matters: - The knee replacement market is expanding on structural demand, not discretionary spending. - The shift affects hospitals, ambulatory surgical centers, implant makers and robotic surgery vendors. - Lower-cost outpatient care and more precise robotic procedures are changing where knee replacements happen and who captures the revenue.

What happened: - Market Research Future said the global knee replacement market will rise from $13.79 billion in 2026 to $20.83 billion by 2035. - The forecast implies a 4.69% compound annual growth rate from 2026 to 2035. - The market base was estimated at $13.17 billion in 2025. - The report was issued July 7, 2026. - A free sample and detailed report are available.

The details: - The report ties growth to aging global demographics, rising obesity, robotic-assisted surgical adoption and outpatient reimbursement reforms. - The United Nations projects the global population age 65 and older will surpass 1.6 billion by 2050. - The World Health Organization estimates more than 890 million adults worldwide live with obesity. - The World Health Organization said more than 528 million people lived with osteoarthritis in 2019, up more than 113% since 1990. - In the U.S., the American Joint Replacement Registry projects primary knee procedures could exceed 3.5 million per year by 2030. - Global capital spending on robotic knee surgery systems approached $1.8 billion in 2024. - CMS removed total knee replacement from the Medicare inpatient-only list in 2020, accelerating migration to ambulatory surgical centers. - By 2024, about 35% of primary knee replacements in the U.S. were performed in outpatient settings, up from less than 5% in 2018. - By 2028, about 50% of primary knee replacements in the U.S. are expected to be outpatient procedures. - The report says ASC facility costs run 30% to 45% lower than traditional inpatient episodes, with patient satisfaction scores equivalent or better. - Total knee replacement led product revenue with about 65.5% share in 2025. - Partial knee replacement was the fastest-growing product segment, with a 5.95% CAGR from 2026 to 2035. - Patellofemoral replacement generated about $0.42 billion in 2025. - Revision systems and tumor prostheses are projected to grow at 4.10% CAGR from 2026 to 2035. - Manual instrumentation held about 48.0% of technology revenue in 2025. - Robotic-assisted surgery was the fastest-growing technology segment, with an 11.85% CAGR from 2026 to 2035. - Computer-navigated and other technologies generated $1.15 billion in 2024. - Hospitals held about 57.5% of end-user share in 2025. - Ambulatory surgical centers were the fastest-growing end-user segment, with a 9.25% CAGR from 2026 to 2035. - Specialty orthopedic clinics and other facilities generated $0.78 billion in 2025. - North America held about 37.8% of the market in 2025. - Europe was the second-largest region at $3.71 billion in 2025. - Asia-Pacific was the fastest-growing region, with a 13.45% CAGR from 2026 to 2035. - The Middle East and Africa is forecast to grow at 5.85% CAGR from 2026 to 2035. - South America held 6.8% of the market in 2025.

Between the lines: - Robotic surgery is moving from a premium differentiator to a core growth engine as utilization rises and lease-based financing lowers upfront costs. - The outpatient shift is likely to move margin and negotiating power away from large hospital systems and toward physician-owned ambulatory networks. - Asia-Pacific growth is being amplified by policy, pricing and access changes, including China's volume-based procurement and India's wider public coverage. - The competitive field remains concentrated, but the report suggests innovation in robotics, AI planning and patient-specific implants will protect leaders from faster commoditization. - Zimmer Biomet's FDA approval for the Oxford Cementless Partial Knee in November 2024 and Stryker's 3,000-plus cumulative Mako installations show how product and platform advantages are shaping share.

What's next: - The report expects integrated AI-navigation platforms to become standard in high-volume centers by 2030. - Machine-learning tools trained on registry data are expected to improve implant sizing, rotation and ligament balance. - Personalized 3D-printed implants and smart implants with embedded sensors are likely to move from development into broader use in the early 2030s. - Instrumented implants could represent an additional $800 million opportunity by 2033, with potential to cut revision rates by 15% to 20%. - Robotic-assisted and outpatient procedures are likely to take a larger share of U.S. knee replacement volume over the next several years.

The bottom line: - Knee replacement demand is set to keep climbing through 2035 as aging, obesity, robotics and outpatient care reinforce one another across the market.